ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Anti-Thymocyte Globulin versus Interleukin-2 Receptor Antagonist and Deceased-Donor Kidney Transplant Outcomes among Older Recipients

J. Ahn1, S. Bae1, K. Lentine2, M. Schnitzler2, G. Hess3, D. Segev1, M. McAdams-DeMarco1

1Johns Hopkins University, Baltimore, MD, 2Saint Louis University, St. Louis, MO, 3Drexel University, Philadelphia, PA

Meeting: 2020 American Transplant Congress

Abstract number: 11

Keywords: Efficacy, Elderly patients, Induction therapy, Kidney transplantation

Session Information

Session Name: Kidney Immunosuppression: Induction Therapy

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:27pm-4:39pm

Location: Virtual

*Purpose: Kidney transplantation (KT) has been growing treatment option for older end-stage renal disease patients. Although lymphocyte-depleting agents are considered to be superior than interleukin-2 receptor antagonist showing a reduced risk of rejection in general, there is sparse research on the choice of induction immunosuppressants for older KT recipients. Older recipients experience a compromised immune response due to aging so that specific induction treatment strategy is required. Therefore, we aim to compare the association of rabbit anti-thymocyte globulin (rATG) (versus basiliximab) and KT outcomes between older (≥65 years) and younger (<65 years) KT recipients.

*Methods: Using the United States Renal Data System, we identified 36,719 first-time KT recipients (age ≥18) between January 1, 2010 and December 31, 2016 who received maintenance immunosuppression of tacrolimus, mycophenolate mofetil and steroid at the time of discharge. We estimated adjusted odds ratio (OR) of acute rejection (AR) at 1-year post-KT and hazard ratios (HR) of death-censored graft failure (DCGF) and post-KT mortality by using logistic and Cox regression. Relative time to discharge was tested with accelerated failure time model. All models were weighted by using propensity score to adjust for confounders. We studied effect measure modification by age using a Wald test.

*Results: Of the 36,719 recipients, 72.8% received rATG and 27.2% received basiliximab. Overall, rATG was associated with lower odds of AR at 1-year post-KT (OR 0.76, 95% CI 0.65-0.89, p < 0.001) than basiliximab and the association was not modified by age. Compared with basiliximab, risk of mortality associated with rATG was lower among younger KT recipients (HR 0.88, 95% CI 0.79-0.97, p = 0.008) but not differ among older recipients (HR 1.04, 95% CI 0.93-1.16, p = 0.466; interaction p = 0.022). There was no significant evidence that rATG had better beneficial effects on DCGF (HR 0.93, 95% CI 0.85-1.01, p = 0.081; interaction p = 0.326) and time to discharge (HR 0.95, 95% CI 0.88-1.01, p = 0.101; interaction p = 0.074) compared to basiliximab.

 border=

*Conclusions: Among older KT recipients, rATG may reduce the risk of AR compared to basiliximab but may not increase the other three undesirable outcomes. Choice of induction immunosuppression should be tailored by recipient age.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Ahn J, Bae S, Lentine K, Schnitzler M, Hess G, Segev D, McAdams-DeMarco M. Anti-Thymocyte Globulin versus Interleukin-2 Receptor Antagonist and Deceased-Donor Kidney Transplant Outcomes among Older Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/anti-thymocyte-globulin-versus-interleukin-2-receptor-antagonist-and-deceased-donor-kidney-transplant-outcomes-among-older-recipients/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences